Eli Lilly's GLP-1 drugs are at the forefront of a medical revolution, addressing obesity and its downstream diseases which account for ~40% of healthcare costs, with a potential market of over a billion people.
The company has significantly improved R&D productivity by reducing its drug development timeline to 8.5 years through faster decision-making and a higher bar for project continuation, boosting ROI in a sector where it's typically near zero.
Artificial Intelligence is a key strategic focus, already delivering tangible process improvements (e.g., an 8% efficiency gain) and holding the potential to halve drug development times in the future.
Eli Lilly is innovating its business model by launching direct-to-consumer pharmacy services to control the customer experience and adopting a tech-industry cadence of continuous improvement.
8 quotes
Concerns Raised
Scaling production and supply chains to meet the massive potential demand for GLP-1 drugs.
Significant regulatory delays ('drug lag') in key markets like Europe, which hinder patient access and revenue.
The inherent high cost and failure rate of drug development, despite process improvements.
Ethical dilemmas and public pressure surrounding drug pricing and affordability.
Opportunities Identified
The enormous untapped market of over a billion people for obesity and weight management therapies.
Expanding the therapeutic applications of GLP-1 drugs into new areas like addiction (smoking, alcohol) and other chronic diseases.
Leveraging AI to dramatically accelerate drug development timelines and optimize manufacturing processes.
Building a direct relationship with patients through direct-to-consumer pharmacy models to control the customer experience.